<DOC>
	<DOCNO>NCT01429376</DOCNO>
	<brief_summary>The aim present study : 1 . To investigate pulmonary function abnormality ( restriction , obstruction , diffusion impairment , mixed pulmonary defect ) patient chronic heart failure ( CHF ) determine pulmonary abnormality prevail extent . 2 . To determine prevalence , underdiagnosis , overdiagnosis chronic obstructive pulmonary disease ( COPD ) determine spirometry accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criterion patient CHF . 3 . To investigate presence systemic inflammation , measure inflammatory parameter ( leukocyte , platelet , high sensitivity CRP ) , CHF patient without COPD .</brief_summary>
	<brief_title>Pulmonary Function , Chronic Obstructive Pulmonary Disease ( COPD ) Prevalence , Systemic Inflammation Chronic Heart Failure With Without COPD</brief_title>
	<detailed_description>1 . The impact chronic heart failure ( CHF ) pulmonary function incompletely understood remain controversial . It difficult separate contribution stable CHF underlie pulmonary disease confound influence , change due normal ageing , obesity , environmental exposure ( mainly smoke ) , stability disease , history coronary artery bypass grafting , condition lead pulmonary function abnormality . Studies show isolated combined pulmonary function impairment , diffusion impairment , restriction , much less extent airway obstruction common patient CHF contribute perception dyspnoea exercise intolerance . Pulmonary dysfunction increase severity heart failure provide important prognostic information . Most investigator compare pulmonary function CHF patient normal predicted value control subject . However , small body literature address prevalence different pulmonary function abnormality patient CHF . In addition , study include ( potential ) heart transplant recipient , represent one extreme heart failure spectrum . The aim present study investigate prevalence pulmonary function abnormality patient CHF determine pulmonary abnormality prevail extent . 2 . Chronic obstructive pulmonary disease ( COPD ) frequently coexist CHF , lead impaired prognosis well diagnostic therapeutic challenge . However , lung functional data COPD prevalence CHF scarce COPD remain widely undiagnosed misdiagnosed . The reported prevalence rate COPD range 9 41 % European cohorts 11 52 % North American patient heart failure . The purpose study determine prevalence , underdiagnosis , overdiagnosis COPD determine spirometry accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criterion patient CHF . 3 . There abundant evidence increase systemic inflammation CHF COPD remarkable observe similarity inflammation condition . These inflammatory response may provide mechanistic bridge COPD cardiac co-morbidity . However , information regard systemic inflammation CHF COPD coexist . It unknown whether combination two diseases lead increase systemic inflammation comparison CHF alone . The aim study investigate presence systemic inflammation , measure inflammatory parameter ( leukocyte , platelet , high sensitivity CRP ) , CHF patient without COPD .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Chronic heart failure patient leave ventricular systolic dysfunction ( left ventricular ejection fraction &lt; 40 % ) Outpatients New York Heart Association ( NYHA ) class IIV 18 year old Informed consent Patients meet inclusion criterion Patients able cooperate undergo pulmonary function test Other disease lead obstructive lung function : asthma , cystic fibrosis Malignancy bad prognosis ( survival &lt; 6 month ) Hospitalisation pulmonary department past 6 week , case patient pulmonary function test â‰¥ 6 week discharge Patients already participate another study within cardiology department Additional exclusion criterion first primary objective : Disorders/diseases lead pulmonary function impairment : Pulmonary : lung surgery ( lobectomy/pneumectomy ) , parenchymal neoplasm , interstitial lung disease , sarcoidosis , pneumoconioses , lung abscess , lobar pneumonia , post infectious scarring , atelectasis , radiation fibrosis Pleural : diffuse pleural thickening , mesothelioma , pleural effusion due heart failure , pneumothorax Neuromuscular disease : ALS , poliomyelitis , myopathy , bilateral diaphragmatic paralysis , high spinal cord lesion , myasthenia gravis Abdominal : obesity ( BMI &gt; 35 ) ( exclusion restriction prevalence analysis ) Pericardial : major pericardial effusion Large mediastinal process Collagen vascular disease Additional exclusion criterion third primary objective : Active/recent infection Febrile inflammatory disease rheumatoid arthritis Use antibiotic antiinflammatory medication , etanercept , infliximab , systemic use corticosteroid NSAID 's acetylsalicylic acid Malignancy Autoimmune disease Collagenvascular disease Gastrointestinal disease ( inflammatory bowel disease ) Recent operation ( past 3 month ) Renal liver failure Thyroid disease Obstructive sleep apnoea syndrome ( OSAS ) Disorders lead thrombocytopenia/leukocytopenia thrombocytosis/leukocytosis ( hsCRP analysis take place case disorder affect hsCRP )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Chronic heart failure</keyword>
	<keyword>Pulmonary function abnormalities/impairment</keyword>
	<keyword>Restriction</keyword>
	<keyword>Airway obstruction</keyword>
	<keyword>Diffusion impairment</keyword>
	<keyword>Pulmonary function test</keyword>
	<keyword>Chronic obstructive pulmonary disease ( COPD )</keyword>
	<keyword>Prevalence</keyword>
	<keyword>Overdiagnosis</keyword>
	<keyword>Underdiagnosis</keyword>
	<keyword>Systemic inflammation</keyword>
	<keyword>Diagnostic Errors</keyword>
</DOC>